title: [Treatment of latent tuberculosis among homeless population. Comparison between wo therapeutic approaches].
abstract: OBJECTIVE
  We aimed to compare treatment adherence and toxicity of isoniazide (H) (6 months) compared with rifampicine (R) + pirazinamide (Z) (2 months) in homeless patients in latent tuberculous infection (LTBI).
  
  
  METHODS
  Randomized and controlled prospective study.
  
  
  RESULTS
  We included 172 patients (116 males and 56 females) with an age average of 42.3 (12.8) years; 31 (18%) had recent conversion and 72 (41.8%) had some risk factor of hepatotoxicity. Both bivariate and multivariate analysis (p < 0.001; OR = 5.15 [2.34-11.35]) showed that the treatment was completed by 61.5% of patients administered the R+Z regimen, while it was completed only by 28.2% of those administered H for 6 months. Moreover, treatment was completed by 48.4% of Spanish or foreign patients with legal residence, while it was completed only by 28.6% of immigrant patients with no legal residence (p = 0.044 in bivariate analysis).
  
  
  CONCLUSIONS
  The R+Z regimen for 2 months as treatment of LTBI in homeless patients displays a higher adherence than H for 6 months. There were no differences in toxicity.
authors.affiliation: Programa de Prevención y Control de la Tuberculosis. Ayuntamiento de Madrid. Madrid. Spain. psaludadulto@munimadrid.es
authors.forename: Ignacio
authors.initials: I
authors.lastname: Sánchez-Arcilla
authors.forename: José María
authors.initials: JM
authors.lastname: Vílchez
authors.forename: Manuel
authors.initials: M
authors.lastname: García de la Torre
authors.forename: Xiomara
authors.initials: X
authors.lastname: Fernández
authors.forename: Arturo
authors.initials: A
authors.lastname: Noguerado
mesh_terms: D000328:Adult; D000995:Antitubercular Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006703:Ill-Housed Persons; D006801:Humans; D007538:Isoniazid / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D010349:Patient Compliance; D011446:Prospective Studies; D011718:Pyrazinamide / Q000008:administration & dosage / Q000627:therapeutic use*; D012293:Rifampin / Q000008:administration & dosage / Q000627:therapeutic use*; D014376:Tuberculosis / Q000188:drug therapy*
chemical_list: D000995:Antitubercular Agents; D011718:Pyrazinamide; D007538:Isoniazid; D012293:Rifampin